scholarly journals Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis

Hepatology ◽  
2003 ◽  
Vol 37 (3) ◽  
pp. 520-527 ◽  
Author(s):  
R Velázquez
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Prospective Analysis

S1293 Risk Factors for Hepatocellular Carcinoma in Patients With Liver Cirrhosis

2010 ◽  
Vol 138 (5) ◽  
pp. S-222
Author(s):  
Mirela Danila ◽  
Roxana Sirli ◽  
Adriana Tudora ◽  
Alina Popescu ◽  
Ioan Sporea ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis

Prospective analysis of risk factors for early intrahepatic recurrence of hepatocellular carcinoma following ethanol injection

2000 ◽  
Vol 32 (2) ◽  
pp. 269-278 ◽  
Author(s):  
Khaleque Newaz Khan ◽  
Hiroshi Yatsuhashi ◽  
Kazumi Yamasaki ◽  
Masafumi Yamasaki ◽  
Osami Inoue ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Intrahepatic Recurrence ◽  
Prospective Analysis ◽  
Ethanol Injection

Risk factors for incisional hernia after hepatic resection for hepatocellular carcinoma in patients with liver cirrhosis

Surgery ◽  
2015 ◽  
Vol 158 (6) ◽  
pp. 1669-1675 ◽  
Author(s):  
Hiroto Kayashima ◽  
Takashi Maeda ◽  
Noboru Harada ◽  
Takanobu Masuda ◽  
Atsushi Guntani ◽  
...  
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Incisional Hernia ◽  
Hepatic Resection

scholarly journals Prognostic markers affecting the early recurrence of hepatocellular carcinoma with liver cirrhosis after curative resection

2019 ◽  
Vol 34 (2) ◽  
pp. 123-131 ◽  
Author(s):  
Wan-Joon Kim ◽  
Tae-Wan Lim ◽  
Pyoung-Jae Park ◽  
Sae-Byeol Choi ◽  
Wan-Bae Kim
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Survival Rate ◽  
Curative Resection ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Early Recurrence ◽  
Lymphocyte Ratio ◽  
Recurrence Group

Background: Early recurrence is associated with poor prognosis after curative resection for hepatocellular carcinoma. Thus, we studied which factors, including this inflammation-based scoring system, affect disease recurrence in single hepatocellular carcinoma patients with liver cirrhosis. Methods: A total of 430 consecutive hepatocellular carcinoma patients were enrolled in our institution between January 2002 and December 2015. Survival rate, univariate, and multivariate analyses were performed to identify the variables associated with recurrence and early recurrence especially. Results: The overall survival rate was significantly lower in the early recurrence group than in the non-early recurrence group ( P<0.001). According to the multivariate analysis, protein induced by vitamin K absence or antagonist (PIVKA) greater than 200 ( P=0.035), neutrophil-to-lymphocyte ratio greater than 2.0 ( P<0.001), elevated Glasgow prognostic score ( P=0.003), tumor size greater than 5 cm ( P=0.002), and the presence of lymphovascular invasion ( P=0.002) were significantly different among the groups and affected the early recurrence of hepatocellular carcinoma. The patients were categorized into five levels of risk for early recurrence according to the number of independent risk factors, and patients with no risk factors were set as the reference group. Conclusion: Neutrophil-to-lymphocyte ratio, Glasgow prognostic score, and serum level of PIVKA offer significant prognostic information associated with early recurrence following single lesion hepatocellular carcinoma patients with liver cirrhosis after curative resection.

scholarly journals Risk Factors for Hepatocellular Carcinoma

2018 ◽  
Vol 15 (6) ◽  
pp. 7-20
Author(s):  
Marilena Stoian ◽  
Victor Stoica
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Liver Cancer ◽  
Hepatitis B ◽  
Rate Ratio ◽  
Obesity And Diabetes ◽  
Rate Ratios

AbstractHepatocellular carcinoma (HCC), the third leading cause of cancer deaths worldwide, with incidence rising is expected to increase by another 81% by the year 2020, primarily due to the hepatitis C epidemic. The strongest risk factors for the development of HCC is a hepatitis B (HBV) and hepatitis C (HCV) virus infection, as well as cirrhosis of any cause. Other risk factors that have been reported include exposure to aflatoxin, alcohol, tobacco, obesity and diabetes. To detect potentially curable cases of hepatocellular carcinoma, outpatients with chronic liver disease who have been seen at the Dr. Ion Cantacuzino Hospital, since 10 years and examined periodically with real-time ultrasonography and measurement of serum alpha-fetoprotein.We analyzed the data on these patients for risk factors for hepatocellular carcinoma.The risk of liver cancer in men was 1.33 times higher than in women; patients in their 60s had significantly higher rate ratios (6.46) than patients in their 40s; patients with liver cirrhosis diagnosed at enrollment had significantly higher rate ratios for liver cancer (1.93) than patients with chronic hepatitis. The high serum alpha-fetoprotein level at enrollment was also confirmed as a significant marker for a high risk, regardless of the stage of disease (chronic hepatitis or liver cirrhosis). The serum markers for hepatitis virus -- HBsAg, and anti-HCV - were significantly associated with the risk of liver cancer: the adjusted rate ratios for HBsAg, anti-HBc, and anti-HCV were estimated to be 6.92, 4.54, and 4.09, respectively. Hepatitis B surface antigen (rate ratio 6,92; 95% CI: 2.92 to 16.39) and hepatitis C antibody (rate ratio 4.09; 95% CI: 1.30 to 12.85) showed the most risk for carcinoma.Further studies are required to clarify the roles of other risk factors, including drinking and smoking habits.

scholarly journals Patients with Chronic Hepatitis C - Who Should Not Be Treated?

2000 ◽  
Vol 14 (suppl b) ◽  
pp. 63B-67B
Author(s):  
Andreas Schüler ◽  
Michael Peter Manns
Keyword(s):  
Risk Factors ◽  
Hepatocellular Carcinoma ◽  
Liver Cirrhosis ◽  
Chronic Hepatitis ◽  
Hepatitis C ◽  
Chronic Hepatitis C ◽  
Treatment Side Effects ◽  
Life Conditions ◽  
Therapy Effectiveness ◽  
Receive Treatment

The decision to treat a patient with chronic hepatitis C (CHC) is based on what is known about the risk factors for developing liver cirrhosis or hepatocellular carcinoma, as well as on conditions that contraindicate therapy or impair therapy effectiveness. Several factors, including age, treatment side effects, disease severity, concurrent diseases and life conditions, may render treatment decisions more difficult. This review focuses on identifying CHC patients who should not receive treatment.

Sign in / Sign up

Export Citation Format

Share Document